CJC-1295 (No DAC) vs Sermorelin

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 7 references

CJC-1295 (No DAC) and Sermorelin are different molecules: CJC-1295 (No DAC) is built on human GHRH's first 29 residues, with four substitutions, and Sermorelin is that same 29-residue stretch with none.

CJC-1295 (No DAC)

CJC-1295 (No DAC)

View CJC-1295 (No DAC)
vs
Sermorelin

Sermorelin

View Sermorelin

Structure at a glance

CJC-1295 (No DAC) and Sermorelin are both 29 residues long. Filled: the 4 positions where the residues differ.

CJC-1295 (No DAC)

NH2

Sermorelin

NH2

NH2: C-terminal amide. A raised D marks a D-amino acid. Codes are three-letter amino acid codes.

Chain length
CJC-1295 (No DAC)29 residues
Sermorelin29 residues
Molecular weight
CJC-1295 (No DAC)3,367.97 g/mol
Sermorelin3,357.93 g/mol

Drawn from the product database. Each measure's bars share one scale.

CJC-1295 (No DAC) vs Sermorelin, compared
What it isAn analog of growth hormone-releasing hormone. Built on the GRF(1-29) backbone, with four amino acid substitutions.[1]A 29-residue peptide: the N-terminal fragment of the 44-residue human growth hormone-releasing hormone.
How they relateTwo molecules derived from the same parent, human growth hormone-releasing hormone. CJC-1295 (No DAC) is built on its first 29 residues, with four amino acid substitutions; Sermorelin is that same 29-residue stretch, with none.
CAS number446036-97-186168-78-7
Molecular formulaC152H252N44O42C149H246N44O42S
Molecular weight3,367.97 g/mol3,357.93 g/mol
SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
TargetThe GHRH receptor, a class B G protein-coupled receptor on anterior pituitary somatotrophs.The pituitary GHRH receptor.
Evidence baseIn the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings were generated with the DAC form. Essentially uncharacterized in humans.[2]Human studies, which supported two US approvals, each for one indication: one diagnostic, one therapeutic.[3][4]
Regulatory statusNo approved product in the United States, the European Union or 12 other countries FDA checked.[7]Sermorelin acetate held two US approvals, each for one indication: a diagnostic one in 1990 and a therapeutic one in 1997.[3][4] Both were withdrawn at the sponsor's request, as of June 2009.[3][4] No FDA-approved product containing it has existed since.[3]
Compared head-to-head?Not with this form: the albumin-conjugated DAC form was compared with hGRF(1-29) in rats. No comparison of CJC-1295 (No DAC) with Sermorelin found in PubMed (searched October 2026).[5]
Handling differenceCJC-1295 (No DAC) contains no sulfur, so it carries neither methionine nor cysteine. Sermorelin contains one methionine, which oxidizes on air exposure, and no cysteine.
Where they get confusedThe names overlap: Sermorelin is also called GRF(1-29), and CJC-1295 (No DAC), a different molecule, is also sold as Mod GRF 1-29. Sermorelin's regulatory record does not extend to CJC-1295 (No DAC).

How CJC-1295 (No DAC) and Sermorelin differ

CJC-1295 (No DAC) and Sermorelin are different molecules derived from the same parent, human growth hormone-releasing hormone (GHRH), a 44-residue hypothalamic hormone. Sermorelin is that hormone's N-terminal 29-residue fragment, and the names GRF(1-29) and GHRH(1-29) both refer to it. It carries no substitutions. CJC-1295 (No DAC) is built on the same 29-residue fragment, with four amino acid substitutions. It is also sold as Modified GRF(1-29), a name that states that construction more plainly. In the literature reviewed for Sermorelin, the overlapping name Mod GRF 1-29 is recorded as belonging to a molecule other than Sermorelin. Both compounds act at the pituitary GHRH receptor.

In the literature reviewed for CJC-1295 (No DAC), the pharmacokinetic findings, in rats and healthy volunteers, came from CJC-1295 with DAC, whose albumin-binding linker CJC-1295 (No DAC) lacks. CJC-1295 (No DAC) itself is essentially uncharacterized in humans.[2] The literature reviewed for CJC-1295 (No DAC) reports no human safety data for CJC-1295 (No DAC) itself. In the literature reviewed for Sermorelin, nothing transfers to CJC-1295 (No DAC). In an August 2026 PubMed search, most of the 331 records naming Sermorelin used it as a diagnostic reagent rather than as the compound under study.[6] In the literature reviewed for Sermorelin, human safety data from studies in adults are sparse and short-term.

FDA's 2024 review found no approved product containing any form of CJC-1295 in the United States, the European Union or 12 other countries.[7] Saying sermorelin acetate is FDA approved is false, and saying it was never FDA approved is equally false. It held two US approvals, each for one indication: a diagnostic one in 1990 and a therapeutic one in 1997.[3][4] Both were withdrawn at the sponsor's request, as of June 2009.[3][4] Sermorelin's regulatory record belongs to Sermorelin alone and does not extend to CJC-1295 (No DAC). Sermorelin acetate was the active ingredient of prescription medicines, since withdrawn. The material supplied here is a research-grade preparation and is not one of those medicines.

CJC-1295 (No DAC) carries a D-alanine at position two, a single-position inversion; Sermorelin's backbone is ordinary L-configuration throughout. CJC-1295 (No DAC) contains no sulfur, so it carries neither methionine nor cysteine, and no disulfide or sulfoxide can form. Sermorelin contains a single methionine, which oxidizes to a sulfoxide on air exposure, and no cysteine.

Have CJC-1295 (No DAC) and Sermorelin been compared directly?

In the literature reviewed for CJC-1295 (No DAC), a rat study by Jette and colleagues compared the albumin-conjugated DAC form with hGRF(1-29). The literature reviewed for CJC-1295 (No DAC) does not state that comparator's C-terminal form. Results are reported for each compound in that model. The material Jette and colleagues identified as CJC-1295 was that conjugate, not the core sold as CJC-1295 (No DAC). No comparison of CJC-1295 (No DAC) with Sermorelin was found in a PubMed search run in October 2026.[5] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is CJC-1295 (No DAC) the same as Sermorelin?+

CJC-1295 (No DAC) and Sermorelin are different molecules derived from the same parent, human growth hormone-releasing hormone. CJC-1295 (No DAC) is built on that hormone's first 29 residues, with four amino acid substitutions. Sermorelin is that same 29-residue stretch, with no substitutions.

Does research on Sermorelin apply to CJC-1295 (No DAC)?+

In the literature reviewed for Sermorelin, nothing transfers to CJC-1295 (No DAC), a different molecule. CJC-1295 (No DAC) itself is essentially uncharacterized in humans.

Is CJC-1295 (No DAC) or Sermorelin approved?+

CJC-1295 (No DAC) has no US approval, while sermorelin acetate held two US approvals, both withdrawn at the sponsor's request. Sermorelin acetate was the active ingredient of prescription medicines, since withdrawn. The material supplied here is a research-grade preparation and is not one of those medicines. Sermorelin's regulatory record does not extend to CJC-1295 (No DAC).

References

  1. 1
    Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PMID 15817669.
  2. 2
    Dominikowski A, et al. Front Endocrinol (Lausanne) 2026. PMID 42395176. DOI 10.3389/fendo.2026.1822475. Narrative review.
  3. 3
    US Food and Drug Administration, Drugs@FDA. Records for the two sermorelin acetate applications; retrieved via the openFDA drug/drugsfda endpoint, 28 August 2026. Two applications and three products, all marketing status Discontinued.
  4. 4
    US Food and Drug Administration. Federal Register notice on the withdrawn sermorelin acetate products. 78 FR 14095, 4 March 2013, document 2013-04827. Full text retrieved from govinfo.gov, 28 August 2026.
  5. 5

    PubMed search, 3 October 2026 (records to 2 October 2026)

    16 records; none was a direct comparison of CJC-1295 (No DAC) with Sermorelin.

    Exact query (NCBI E-utilities): ("CJC-1295"[tiab] OR "CJC 1295"[tiab] OR "CJC1295"[tiab] OR "modified GRF"[tiab] OR "mod GRF"[tiab] OR "modGRF"[tiab] OR "tetrasubstituted"[tiab] OR "DAC-free"[tiab] OR "non-DAC"[tiab] OR "without DAC"[tiab] OR "no DAC"[tiab]) AND ("sermorelin"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH(1-29)"[tiab] OR "GRF 1-29"[tiab] OR "GHRH 1-29"[tiab] OR "hGRF(1-29)"[tiab] OR "growth hormone releasing hormone 1-29"[tiab] OR "growth hormone releasing factor 1-29"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  6. 6
    PubMed searches via NCBI E-utilities, 28 August 2026. "sermorelin" returns 331 records, most using it as a diagnostic reagent.
  7. 7
    US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing document, 4 December 2024. Regulatory document, not peer-reviewed. fda.gov
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

CJC-1295 (No DAC) vs CJC-1295 with DAC

CJC-1295 with DAC is a chemically modified form of CJC-1295 (No DAC); the DAC-free peptide is essentially uncharacterized in humans.

Read Comparison
Comparison

CJC-1295 (No DAC) vs IGF-1 LR3

CJC-1295 (No DAC), a 29-residue peptide, and IGF-1 LR3, an 83-residue protein, are different molecules from different parents.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Ipamorelin

CJC-1295 (No DAC) is a synthetic peptide built on human GHRH's first 29 residues; Ipamorelin is a synthetic five-residue peptide.

Read Comparison